Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs
Authors:
Open Access
- 7 June 2016
- book chapter
- Published by Springer Nature
- Vol. 39, 261-295
Abstract
Drug-discrimination procedures empirically evaluate the control that internal drug states have over behavior. They provide a highly selective method to investigate the neuropharmacological underpinnings of the interoceptive effects of drugs in vivo. As a result, drug discrimination has been one of the most widely used assays in the field of behavioral pharmacology. Drug-discrimination procedures have been adapted for use with humans and are conceptually similar to preclinical drug-discrimination techniques in that a behavior is differentially reinforced contingent on the presence or absence of a specific interoceptive drug stimulus. This chapter provides a basic overview of human drug-discrimination procedures and reviews the extant literature concerning the use of these procedures to elucidate the underlying neuropharmacological mechanisms of commonly abused illicit drugs (i.e., stimulants, opioids, and cannabis) in humans. This chapter is not intended to review every available study that used drug-discrimination procedures in humans. Instead, when possible, exemplary studies that used a stimulant, opioid, or Δ9-tetrahydrocannabinol (the primary psychoactive constituent of cannabis) to assess the discriminative-stimulus effects of drugs in humans are reviewed for illustrative purposes. We conclude by commenting on the current state and future of human drug-discrimination research.Keywords
This publication has 156 references indexed in Scilit:
- Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ9-THC in humans discriminating Δ9-THCDrug and Alcohol Dependence, 2012
- A Proof-of-Concept Randomized Controlled Study of Gabapentin: Effects on Cannabis Use, Withdrawal and Executive Function Deficits in Cannabis-Dependent AdultsNeuropsychopharmacology, 2012
- AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in micePsychopharmacology, 2011
- Discriminative Stimulus Effects of Tramadol in HumansThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Separate and combined effects of the cannabinoid agonists nabilone and Δ9-THC in humans discriminating Δ9-THCDrug and Alcohol Dependence, 2011
- Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonistEuropean Journal of Pharmacology, 2011
- Antagonism of ∆9-THC induced behavioral effects by rimonabant: Time course studies in ratsEuropean Journal of Pharmacology, 2010
- Monoaminergic Psychomotor Stimulants: Discriminative Stimulus Effects and Dopamine EffluxThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Mu opioid receptor modulation of somatodendritic dopamine overflow: GABAergic and glutamatergic mechanismsEuropean Journal of Neuroscience, 2009
- Substitution profile of Δ9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Δ9-tetrahydrocannabinolPsychopharmacology, 2008